Pregnancy & Lactation : הריון/הנקה

4.6 Fertility, pregnancy and lactation
Women of childbearing potential/contraception in males and females
Women of childbearing potential have to use effective contraception during treatment.
Decreased serum estradiol and progesterone concentrations have been reported in women treated with human leukocyte interferon.

Intron A must be used with caution in fertile men.

Combination therapy with ribavirin
Ribavirin causes serious birth defects when administered during pregnancy. Extreme care must be taken to avoid pregnancy in female patients or in partners of male patients taking Intron A in combination with ribavirin. Females of childbearing potential must use an effective contraceptive during treatment and for 4 months after treatment has been concluded. Male patients or their female partners must use an effective contraceptive during treatment and for 7 months after treatment has been concluded (see ribavirin SPC).

Pregnancy
There are no adequate data from the use of interferon alfa-2b in pregnant women.
Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Intron A is to be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Combination therapy with ribavirin
Ribavirin therapy is contraindicated in women who are pregnant.

Breast-feeding
It is not known whether the components of this medicinal product are excreted in human milk.
Because of the potential for adverse reactions in nursing infants, nursing should be discontinued prior to initiation of treatment.